CLMT: $347 million of Q3 Adjusted EBITDA as specialty strength and renewables growth accelerated deleveraging
Calumet, Inc. reported Q3 2026 Adjusted EBITDA of $347 million, driven by specialty products and Montana Renewables. The company continued deleveraging and expects future growth from specialty supply constraints and MaxSAF expansion, according to management.
How this was made

The 30-second read
Why it matters
The earnings beat provides a fresh catalyst for the stock, with potential upside in the near term.
Market read
First‑time disclosure of Q3 EBITDA offers a trading opportunity for CLMT.
What to watch
Potential supply constraints in specialty products could cap future upside.
Background
Calumet Inc. released its Q3 2026 earnings summary, highlighting EBITDA and renewables growth.
Ticker impact
Q3 2026 Adjusted EBITDA of $347 million reported, indicating strong specialty and renewables performance.
likely upside as investors price in stronger-than-expected earnings
The disclosed EBITDA figure is new and material for a mid‑cap industrial company, providing a clear catalyst for short‑term trading.
Market effects
Strength in specialty chemicals and renewables may lift peers in the industrial sector.
U.S. industrial equities could see modest gains.
Limited to U.S. markets; no immediate global ripple.
Counterpoint
If the EBITDA growth is driven by one‑off items, the rally could be short‑lived.
Key entities
- companyCalumet Inc.
U.S. industrial chemicals and renewables producer.


